Dasatinib is a tyrosine kinase inhibitor used to treat certain types of leukemia, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1]. It is typically available in 50 mg and 100 mg tablet strengths [1].
What is Dasatinib prescribed for?
Dasatinib is prescribed for adults with newly diagnosed chronic myeloid leukemia in the chronic phase (CML-CP) [1]. It is also used for patients with CML-CP who are resistant or intolerant to prior therapy, and for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to prior therapy [1].
How does Dasatinib work?
Dasatinib functions by inhibiting multiple tyrosine kinases, including BCR-ABL and SRC family kinases [1]. By blocking these enzymes, it prevents the growth of cancer cells [1].
When does Dasatinib's patent expire?
The patent landscape for dasatinib is complex, with multiple patents covering its composition of matter, methods of use, and manufacturing processes [2]. DrugPatentWatch.com tracks these patents and their expiry dates. For specific patent expiry information, users can consult resources like DrugPatentWatch.com [2].
What are the common side effects of Dasatinib?
Common side effects of dasatinib include fluid retention (effusions), diarrhea, headache, rash, nausea, fatigue, muscle spasms, bleeding events, abdominal pain, and decreased appetite [1]. Serious side effects can include severe fluid retention, cardiac disorders, bleeding, myelosuppression, and liver problems [1].
Are there generic versions of Dasatinib available?
As patents expire, generic versions of drugs can become available. Information on the availability of generic dasatinib can be found by tracking patent expiries and regulatory approvals for generic manufacturers. DrugPatentWatch.com provides data on patent statuses that inform generic entry [2].
How does Dasatinib compare to other CML treatments?
Dasatinib is one of several tyrosine kinase inhibitors (TKIs) used to treat CML. Other TKIs include imatinib, nilotinib, bosutinib, and ponatinib [3]. The choice of TKI depends on factors such as the patient's specific genetic mutations, prior treatment history, tolerability, and physician recommendation [3]. Each TKI has a different efficacy and side effect profile [3].
What is the typical dosage of Dasatinib?
The typical starting dose for newly diagnosed CML-CP is 100 mg once daily [1]. For patients with CML-CP resistant or intolerant to prior therapy, or for Ph+ ALL, the recommended starting dose is 140 mg once daily [1]. Doses may be adjusted based on patient response and tolerability [1]. The 50 mg tablet strength is used for dose adjustments or in specific patient populations.
What clinical data supports Dasatinib's use?
Clinical trials have demonstrated dasatinib's efficacy in achieving hematologic, cytogenetic, and molecular responses in patients with CML and Ph+ ALL [1]. Studies such as the DASISION trial (for newly diagnosed CML) and the CA180-034 trial (for resistant/intolerant CML) have provided key data on its effectiveness [1].
What are the regulatory approvals for Dasatinib?
Dasatinib is approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of specific types of leukemia [1].
What are the potential risks or contraindications for Dasatinib?
Dasatinib carries potential risks, including myelosuppression (low blood cell counts), fluid retention, cardiac disorders, bleeding events, and potential for tumor lysis syndrome [1]. It is contraindicated in patients with hypersensitivity to dasatinib [1]. Patients should discuss all potential risks with their healthcare provider.
---
Sources:
[1] https://www.sprycel.com/
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389475/